BR100 Increased By (1.02%)
BR30 Increased By (1.71%)
KSE100 Increased By (0.58%)
KSE30 Increased By (0.65%)
BECO 6.03 Increased By ▲ 0.26 (4.51%)
BML 52.75 Decreased By ▼ -0.25 (-0.47%)
BOP 34.25 Increased By ▲ 0.26 (0.76%)
CNERGY 8.16 Increased By ▲ 0.05 (0.62%)
DCL 12.34 Increased By ▲ 0.14 (1.15%)
FCCL 53.89 Increased By ▲ 1.06 (2.01%)
FCSC 5.22 Increased By ▲ 0.15 (2.96%)
FFL 18.03 Increased By ▲ 0.08 (0.45%)
FNEL 1.30 Increased By ▲ 0.01 (0.78%)
HUMNL 11.00 Increased By ▲ 0.12 (1.1%)
KEL 8.11 Increased By ▲ 0.09 (1.12%)
KOSM 5.38 Decreased By ▼ -0.14 (-2.54%)
MLCF 88.05 Increased By ▲ 1.54 (1.78%)
NBP 186.48 Increased By ▲ 1.32 (0.71%)
PACE 10.72 Increased By ▲ 0.14 (1.32%)
PAEL 39.94 Increased By ▲ 0.52 (1.32%)
PIAHCLA 26.17 Decreased By ▼ -0.05 (-0.19%)
PIBTL 17.32 Increased By ▲ 0.65 (3.9%)
PPL 232.78 Increased By ▲ 4.60 (2.02%)
PRL 34.95 Increased By ▲ 0.27 (0.78%)
PTC 67.56 Increased By ▲ 2.23 (3.41%)
SEARL 90.93 Increased By ▲ 0.80 (0.89%)
SSGC 27.17 Increased By ▲ 0.57 (2.14%)
TELE 8.57 Increased By ▲ 0.29 (3.5%)
THCCL 60.13 Increased By ▲ 1.63 (2.79%)
TPLP 8.76 Increased By ▲ 0.54 (6.57%)
TREET 24.54 Increased By ▲ 0.01 (0.04%)
TRG 71.75 Increased By ▲ 2.04 (2.93%)
WAVES 9.98 Increased By ▲ 0.04 (0.4%)
WTL 1.26 Decreased By ▼ -0.02 (-1.56%)

LAHORE: Getz Pharma manufactures safe and efficacious medicines in its WHO, PIC/s, and EAEU pre-qualified manufacturing facility, a spokesman of the company, said.

Responding to false information about its product Risek IV 40 mg injection on electronic and social media, the spokesman said. “On February 12, 2024, the Federal Inspector of Drugs-IV, while conducting market surveillance in Moro, Sindh, identified counterfeit Risek 40mg IV injections at the premises of M/s Qalanari Medicos on Hospital Road, Moro, Nowsheroferoz.

Samples were sent for testing, including confirmation by Getz Pharma. We confirmed the sample as counterfeit, not manufactured by us, and provided a comparative analysis report to authorities, urging action.”

Getz Pharma condemns the misreporting by the electronic media of the Alert issued by Drug Regulatory Authority of Pakistan (DRAP) as if our manufactured product was deemed spurious or counterfeit, requiring recall.

Copyright Business Recorder, 2024

Comments

Comments are closed for this article.